A Comparison of Two Total Hip Replacements: Hip Resurfacing System Versus Mallory-Head/Exeter

NCT ID: NCT00116948

Last Updated: 2014-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-01-31

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare two total hip replacement systems: Hip Resurfacing System (ReCap) versus Mallory-Head/Exeter.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In Denmark approximately 7000 primary hip replacements are implanted yearly, and the incidence is rising with the increasingly aging population. For older patients, the incidence of later revisions of hip implantation is low. Unfortunately, this is not true for younger patients. Approximately 20% of patients under 55 years of age at the time of surgery must have the hip implant renewed within 10 years.

This is primarily because of the wear generated by polyethylene debris. The polyethylene is associated with osteolysis in the proximity of the prosthesis leading to failure of the prosthesis.

This unsatisfactory result has led to the development of an alternative hip prosthesis especially to benefit younger and physically active people. The new prosthesis should produce less inflammatory debris and less osteolysis induced failure.

To avoid the polyethylene particles, a new type of prosthesis has been made articulating metal on metal. The Hip Resurfacing System consists of an alloy of chrome - cobalt - molybdenum. Another point of interest for this prosthesis is also the size of the articulating surfaces which are bigger than usual. This will theoretically participate in the generation of metal ions.

Study objectives:

* This randomised prospective study will investigate the emission of Co-, Cr- and Mb-ions from Hip Resurfacing System and Mallory-Head/Exeter implants, respectively. The emission is measured as the ion concentration in the urine and is correlated to the inflammatory response in fasting plasma before and after the operation.
* To assess the walking pattern postoperatively using a 3D gait analysis, Vicon Polygon.
* To assess the postoperative recovery using the Harris hip score and visual analogue scale.
* The migration of acetabular components will be evaluated by RSA, performing radiostereometric analyses at the Orthopaedic Center, Aarhus University Hospital. The follow-up RSA will be scheduled for week 1, as well as 3 months, 12 months, 24 months, and 5 years after surgery. Bone mineral density around the implanted femoral component will be examined by DEXA scan at week 1, as well as 1 year and 2 years after surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ReCap, Hip resurfacing system, Biomet

ReCap total hip arthroplasty inserted according to manufactures manual.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with primary hip osteoarthrosis (OA).
* Informed patient consent in writing.
* Sufficient bone density to allow uncemented implantation of an acetabular component.

Exclusion Criteria

* Presence of other metal implants.
* Working exposure of chrome, cobalt or molybdenum.
* Ingestion of multivitamin or medication containing chrome, cobalt or molybdenum.
* Kidney disease
* Hip joint dysplasia
* Patients with neuromuscular or vascular disease in the affected leg.
* Patients who regularly take non-steroid anti-inflammatory drugs (NSAID) and cannot interrupt intake for the postoperative phase of the study.
* Patients with fracture sequelae.
* Female patients of childbearing capacity.
* Sequelae to previous hip joint disorder in childhood
Minimum Eligible Age

50 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biomet Merck Aps,Horsens, Denmark

UNKNOWN

Sponsor Role collaborator

Gigtforeningen

OTHER

Sponsor Role collaborator

Sahva A/S, Borgervænget 5-7, København Ø, Denmark

UNKNOWN

Sponsor Role collaborator

Danske Fysioterapeuter

OTHER

Sponsor Role collaborator

Regionshospitalet Silkeborg

OTHER

Sponsor Role collaborator

Finnish Institute of Occupational Health

OTHER

Sponsor Role collaborator

Regionshospitalet Hammel Neurocenter

OTHER

Sponsor Role collaborator

University of Aarhus

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kjeld Søballe, MD., Prof.

Role: PRINCIPAL_INVESTIGATOR

Orthopaedic Center, Aarhus University Hospital, Aarhus, Denmark

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Orthopaedic Center, Aarhus University Hospital

Aarhus, Jylland, Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20030289

Identifier Type: -

Identifier Source: org_study_id